Hims and Hers (NYSE: HIMS) Launches Generic Semaglutide in Canada After Novo Nordisk Patent Lapse
Semaglutide just got a lot more accessible in Canada. Hims and Hers, a well-known telehealth company, has launched generic semaglutide offerings after Novo Nordisk’s patent protection expired. Translation: researchers, clinics, and anyone following GLP-1 agonist developments can expect new price points and wider availability of this popular peptide.
foreignpolicyjournal.com
“Hims and Hers (NYSE: HIMS) Launches Generic Semaglutide in Canada After Novo Nordisk Patent Lapse foreignpolicyjournal.com”
Why does this matter? Semaglutide, a GLP-1 analog, has been the backbone of several research projects exploring metabolic health, appetite regulation, and glucose control. Patent barriers kept it pricey and limited to a handful of authorized suppliers. That wall just fell—at least in Canada.
Key changes with this move:
More suppliers will enter the market, increasing competition and dropping costs.
Researchers may find it easier to source semaglutide for their work.
The generic rollout could pressure other regions to follow suit when patents lapse.
This isn’t just about Hims and Hers. The Canadian launch signals a shift in how research peptides like semaglutide are distributed and sourced. Labs and clinics that previously struggled with cost or access now have more options, and new vendors are likely to pop up. Anyone looking to compare sources or find new suppliers should watch the vendor directory for updates.
Semaglutide research is about to get a lot more robust north of the border. More competition means better access—good news for anyone exploring the science behind GLP-1 peptides.
Related Reading
Saitama University researchers discover that a natural peptide aptamer switches between two target proteins depending on metal ions
News · Eur J Vasc Endovasc SurgThe STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · EIN PresswirePeptide Therapeutics Market Revenue To Cross $222 Billion By 2030 Supported By Rising Demand
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.